All In MedTech

Device Trial Radar · NCT04529616

Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual Outcomes

Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

79

Actual

Start

May 22, 2020

Primary completion

Oct 1, 2022

Study completion Oct 1, 2022

Sponsor

Lead sponsor
RxSight, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 27, 2020

More device trials from this sponsor

Design

Study type
Interventional
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate, for the visual correction of aphakia, whether the RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) can be used to improve visual outcomes after performing adjustments of the LAL with the LDD. This is an exploratory study. No primary effectiveness endpoints will be identified.

Conditions

  • Aphakia
  • Cataract

Interventions

  • Light Adjustable lens (LAL) and Light Delivery Device (LDD)Device

    Eligible eyes will receive Light adjustable lens with Light delivery Device treatments

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or BetterTime frame: 3 months post op
  2. Proportion of Eyes Simultaneously With (1) Monocular UCDVA of 20/25 or Better and (2) Monocular Uncorrected Intermediate Visual Acuity (UCIVA) of 20/32 or Better and (3) Monocular Uncorrected Near Visual Acuity (UCNVA) of 20/40 or BetterTime frame: 12 months post op

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CODET Vision Institute

    Tijuana, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.